Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20.

2.

Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.

Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Anticancer Res. 2020 Jan;40(1):299-304. doi: 10.21873/anticanres.13953.

PMID:
31892580
3.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2019 Nov 20. pii: theoncologist.2019-0541. doi: 10.1634/theoncologist.2019-0541. [Epub ahead of print]

4.

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A.

Med Oncol. 2019 Jun 3;36(7):63. doi: 10.1007/s12032-019-1288-7.

PMID:
31161433
5.

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy.

Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A.

Cancers (Basel). 2018 Nov 16;10(11). pii: E454. doi: 10.3390/cancers10110454.

6.

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.

Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Cancer Chemother Pharmacol. 2019 Jan;83(1):123-129. doi: 10.1007/s00280-018-3711-8. Epub 2018 Oct 30.

Supplemental Content

Loading ...
Support Center